Literature DB >> 7685739

Specificity of Cryptococcus neoformans factor sera determined by enzyme-linked immunosorbent assay and dot enzyme assay.

T Belay1, R Cherniak, T Shinoda.   

Abstract

An indirect enzyme-linked immunosorbent assay (ELISA) and a dot enzyme assay (DEA) were used to determine the specificities of Cryptococcus neoformans factor sera to serotype type-specific capsular polysaccharides, glucuronoxylomannans (GXMs). Pure and chemically characterized GXMs were obtained from representative isolates of C. neoformans serotypes A, B, C, and D. Distinctive specificity patterns and quantitative differences were observed for each factor serum when the selected GXMs were studied by ELISA. The specificity patterns for each factor serum determined by DEA almost completely paralleled the ELISA results. The serotype specificities demonstrated by ELISA and DEA were similar to previously reported results that were obtained by slide agglutination studies of whole cells. On the basis of the ELISA and DEA activity patterns, factor sera 5, 6, and 8 were specific for serotypes B, C, and D, respectively; factor serum 1 was strongly reactive to all serotypes; factor serum 2 was specific for serotypes A, B, and D; factor serum 3 was specific for serotypes A and D; and factor serum 4 was specific for serotypes B and C. The specificity of factor serum 7 for serotype A was demonstrated by DEA only. Structural variation was indicated among the serotype C isolates studied because a unique activity pattern versus factor serum 6 was observed for each isolate. The quantitative differences in the activity of the GXMs from five serotype C isolates suggest that mannopyranoside residues substituted O-2 and O-4 with xylose are essential elements of the determinant responsible for the observed activity of factor 6. No significant differences in activity patterns and specificities of factor serum 6 were observed when O-deacetylated GXMs were substituted for the native GXMs. Our results show that ELISA and DEA are valuable techniques for the serological analysis of cryptococcal factor sera and GXMs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7685739      PMCID: PMC280934          DOI: 10.1128/iai.61.7.2879-2885.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  23 in total

1.  Serologic grouping of Cryptococcus neoformans.

Authors:  D E Wilson; J E Bennett; J W Bailey
Journal:  Proc Soc Exp Biol Med       Date:  1968-03

2.  Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A.

Authors:  R Cherniak; E Reiss; M E Slodki; R D Plattner; S O Blumer
Journal:  Mol Immunol       Date:  1980-08       Impact factor: 4.407

3.  Cryptococcosis in the acquired immunodeficiency syndrome.

Authors:  J A Kovacs; A A Kovacs; M Polis; W C Wright; V J Gill; C U Tuazon; E P Gelmann; H C Lane; R Longfield; G Overturf
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

4.  Cryptococcus neoformans. 3. Inhibition of phagocytosis.

Authors:  G S Bulmer; M D Sans
Journal:  J Bacteriol       Date:  1968-01       Impact factor: 3.490

5.  Epidemiologic differences between the two varieties of Cryptococcus neoformans.

Authors:  K J Kwon-Chung; J E Bennett
Journal:  Am J Epidemiol       Date:  1984-07       Impact factor: 4.897

6.  Chemical characterization of capsular polysaccharide from Cryptococcus neoformans serotype A-D.

Authors:  R Ikeda; A Nishikawa; T Shinoda; Y Fukazawa
Journal:  Microbiol Immunol       Date:  1985       Impact factor: 1.955

7.  Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment.

Authors:  A Zuger; E Louie; R S Holzman; M S Simberkoff; J J Rahal
Journal:  Ann Intern Med       Date:  1986-02       Impact factor: 25.391

8.  Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates.

Authors:  R Ikeda; T Shinoda; Y Fukazawa; L Kaufman
Journal:  J Clin Microbiol       Date:  1982-07       Impact factor: 5.948

9.  Enzyme-linked immunosorbent assays in murine cryptococcosis.

Authors:  E N Scott; H G Muchmore; F G Felton
Journal:  Sabouraudia       Date:  1981-12

Review 10.  Capsular polysaccharides of Cryptococcus neoformans.

Authors:  A K Bhattacharjee; J E Bennett; C P Glaudemans
Journal:  Rev Infect Dis       Date:  1984 Sep-Oct
View more
  6 in total

1.  Production of agglutinating monoclonal antibody against antigen 8 specific for Cryptococcus neoformans serotype D.

Authors:  R Ikeda; S Nishimura; A Nishikawa; T Shinoda
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

2.  Serotyping of Cryptococcus neoformans by dot enzyme assay.

Authors:  T Belay; R Cherniak; E B O'Neill; T R Kozel
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

3.  Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay.

Authors:  T Belay; R Cherniak; T R Kozel; A Casadevall
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

Review 4.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.

Authors:  T G Mitchell; J R Perfect
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

5.  Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis.

Authors:  R Cherniak; L C Morris; T Belay; E D Spitzer; A Casadevall
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

6.  Determination of antigen binding specificities of Cryptococcus neoformans factor sera by enzyme-linked immunosorbent assay.

Authors:  T Belay; R Cherniak
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.